Edwards Lifesciences stock analysis
Edwards Lifesciences (0REN) Share Price & Analysis
0REN Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 51.70B
- Enterprise Value
- CHF 46.02B
- Total Cash (Recent Filing)
- CHF 4.64B
- Total Debt (Recent Filing)
- CHF 704.50M
- Price to Earnings (P/E)
- 60.5
- Beta
- N/A
- Next Earnings
- Jan 27, 2027 (Est.)
- EPS Estimate
- 0.56
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength
Very low leverage and steadily rising equity provide Edwards with financial flexibility to fund research, regulatory programs, and commercial expansion. This balance-sheet strength can help the company absorb operating volatility while preserving capacity to invest in structural-heart opportunities over the next several quarters.
Revenue And EPS Growth Outlook
Raised sales and adjusted EPS guidance indicates that current demand, product adoption, and execution are supporting growth beyond a single product cycle. Management also reaffirmed approximately 10% long-term annual sales growth with EPS leverage, strengthening the outlook for continued earnings expansion.
Clinical And Regulatory Expansion
Multiple approvals and clinically meaningful evidence can expand eligible patient populations, support physician adoption, and reinforce Edwards' position in structural heart. These developments create a broader product and indication base, making future growth less dependent on one procedure or mature market.
Bears Say
Operating Margin Compression
The decline in operating profitability suggests that higher costs, investment intensity, or product mix are absorbing part of the benefit from revenue growth. Unless margins recover, earnings may compound more slowly than sales and the company will have less operating leverage during periods of demand or currency pressure.
Volatile Free Cash Flow
Edwards generates substantial cash, but uneven free-cash-flow momentum and weak conversion in some periods reduce confidence in the consistency of internally funded growth. Continued volatility could constrain the timing of investments, shareholder returns, or other capital-allocation decisions even with a strong balance sheet.
Increasing Competitive Pressure
A plateau in TAVR share gains means future growth must rely more heavily on procedure expansion and new indications rather than continued competitive capture. As additional competitors enter, potential share loss could pressure pricing, volume growth, and the durability of Edwards' leadership in its core franchise.
0REN FAQ
What is Edwards Lifesciences’s market cap?
When is Edwards Lifesciences’s upcoming earnings report date?
How were Edwards Lifesciences’s earnings last quarter?
Is Edwards Lifesciences overvalued?
Does Edwards Lifesciences pay dividends?
What is Edwards Lifesciences’s EPS estimate?
How many shares outstanding does Edwards Lifesciences have?
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Edwards Lifesciences?
What is the TipRanks Smart Score and how is it calculated?
Edwards Lifesciences Stock Smart Score
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Bernard J. Zovighian
- Employees
- 16,000
- Website
- www.edwards.com
- Address
- One Edwards Way, Irvine, CA, 92614, US
Edwards Lifesciences (0REN) Earnings & Revenues
0REN Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Edwards reported better-than-expected third-quarter results, raised full-year sales, TAVR, TMTT and EPS guidance, highlighted broad clinical and regulatory progress, and expressed confidence in durable long-term growth. The main challenges were GAAP EPS impairment, foreign-exchange and tax headwinds, expected fourth-quarter margin phasing, moderating TAVR share gains and the gradual timing of new-indication benefits.
View all GB:0REN earnings summaries0REN Net sales Breakdown
- 73.96% Transcatheter Aortic Valve Replacement
- 9.07% Transcatheter Mitral and Tricuspid Therapies
- 16.96% Surgical Structural Heart












